{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:58:40Z","timestamp":1790488720293,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000288","name":"Royal Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000288","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      In clinical trials of therapy for uncomplicated\n                      <jats:italic>Plasmodium falciparum,<\/jats:italic>\n                      there are usually some patients who fail treatment even in the absence of drug resistance. Treatment failures, which can be due to recrudescence or re-infection, are categorized as \u2018clinical\u2019 or \u2018parasitological\u2019 failures, the former indicating that symptoms have returned. Asymptomatic recrudescence has public health implications for continued malaria transmission and may be important for the spread of drug-resistant malaria. As the number of recrudescences in an individual trial is often low, it is difficult to assess how commonplace asymptomatic recrudescence is, and with what factors it is associated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature review was carried out on clinical trials of artemether-lumefantrine (AL) in patients seeking treatment for symptomatic uncomplicated falciparum malaria, and information on symptoms during treatment failure was recorded. Only treatment failures examined by polymerase chain reaction (PCR) were included, so as to exclude re-infections. A multivariable Bayesian regression model was used to explore factors potentially explaining the proportion of recrudescent infections which are symptomatic across the trials included in the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across 60 published trials, including 9137 malaria patients, 37.8% [95% CIs (26.6\u201349.4%)] of recrudescences were symptomatic. A positive association was found between transmission intensity and the observed proportion of recrudescences that were asymptomatic. Symptoms were more likely to return in trials that only enrolled children aged\u2009&lt;\u200972\u00a0months [odds ratio\u2009=\u20091.62, 95% CIs (1.01, 2.59)]. However, 84 studies had to be excluded from this analysis, as recrudescences were not specified as symptomatic or asymptomatic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      AL, the most widely used treatment for uncomplicated\n                      <jats:italic>P. falciparum<\/jats:italic>\n                      in Africa, remains a highly efficacious drug in most endemic countries. However in the small proportion of patients where AL does not clear parasitaemia, the majority of patients do not develop symptoms again and thus would be unlikely to seek another course of treatment. This continued asymptomatic parasite carriage in patients who have been treated may have implications for drug-resistant parasites being introduced into high-transmissions settings.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-020-03520-1","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T07:30:05Z","timestamp":1607499005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Asymptomatic recrudescence after artemether\u2013lumefantrine treatment for uncomplicated falciparum malaria: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"19","author":[{"given":"Rida","family":"Mumtaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy C.","family":"Okell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6029-1733","authenticated-orcid":false,"given":"Joseph D.","family":"Challenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"3520_CR1","volume-title":"World Malaria Report 2019","author":"WHO","year":"2019","unstructured":"WHO. World Malaria Report 2019. Geneva: World Health Organization; 2019."},{"key":"3520_CR2","volume-title":"Guidelines for the treatment of malaria","author":"WHO","year":"2015","unstructured":"WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.","edition":"3"},{"key":"3520_CR3","first-page":"CD007483","volume":"3","author":"D Sinclair","year":"2009","unstructured":"Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev. 2009;3:CD007483.","journal-title":"Cochrane Database Syst Rev"},{"key":"3520_CR4","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1128\/AAC.44.3.697-704.2000","volume":"44","author":"F Ezzet","year":"2000","unstructured":"Ezzet F, Van Vugt M, Nosten F, Looareesuwan S, White NJ. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother. 2000;44:697\u2013704.","journal-title":"Antimicrob Agents Chemother"},{"key":"3520_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12916-015-0456-7","volume":"13","author":"WorldWide Antimalarial Resistance Network Lumefantrine PKPD Study Group","year":"2015","unstructured":"WorldWide Antimalarial Resistance Network Lumefantrine PKPD Study Group. Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. BMC Med. 2015;13:227.","journal-title":"BMC Med."},{"key":"3520_CR6","doi-asserted-by":"publisher","first-page":"e1002579","DOI":"10.1371\/journal.pmed.1002579","volume":"15","author":"F Kloprogge","year":"2018","unstructured":"Kloprogge F, Workman L, Borrmann S, Tekete M, Lefevre G, Hamed K, et al. Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: a pharmacokinetic-pharmacodynamic meta-analysis. PLoS Med. 2018;15:e1002579.","journal-title":"PLoS Med."},{"key":"3520_CR7","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/infdis\/jit078","volume":"207","author":"DJ Creek","year":"2013","unstructured":"Creek DJ, Bigira V, McCormack S, Arinaitwe E, Wanzira H, Kakuru A, et al. Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in ugandan infants. J Infect Dis. 2013;207:1646\u201354.","journal-title":"J Infect Dis"},{"key":"3520_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/clpt.2011.254","volume":"91","author":"J Tarning","year":"2012","unstructured":"Tarning J, Zongo I, Som\u00e9 FA, Rouamba N, Parikh S, Rosenthal PJ, et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther. 2012;91:497\u2013505.","journal-title":"Clin Pharmacol Ther"},{"key":"3520_CR9","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/cpt.1531","volume":"106","author":"P Chotsiri","year":"2019","unstructured":"Chotsiri P, Denoeud-Ndam L, Baudin E, Guindo O, Diawara H, Attaher O, et al. Severe acute malnutrition results in lower lumefantrine exposure in children treated with artemether-lumefantrine for uncomplicated malaria. Clin Pharmacol Ther. 2019;106:1299\u2013309.","journal-title":"Clin Pharmacol Ther"},{"key":"3520_CR10","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1128\/AAC.01700-12","volume":"57","author":"EM Staehli Hodel","year":"2013","unstructured":"Staehli Hodel EM, Csajka C, Ariey F, Guidi M, Kabanywanyi AM, Duong S, et al. Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and n-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. Antimicrob Agents Chemother. 2013;57:950\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"3520_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s13318-016-0399-1","volume":"42","author":"H Elewa","year":"2017","unstructured":"Elewa H, Wilby KJ. A review of pharmacogenetics of antimalarials and associated clinical implications. Eur J Drug Metab Pharmacokinet. 2017;42:745\u201356.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"3520_CR12","doi-asserted-by":"publisher","first-page":"e84555","DOI":"10.1371\/journal.pone.0084555","volume":"9","author":"K Bruxvoort","year":"2014","unstructured":"Bruxvoort K, Goodman C, Patrick Kachur S, Schellenberg D. How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs. PLoS ONE. 2014;9:e84555.","journal-title":"PLoS ONE"},{"key":"3520_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1475-2875-13-7","volume":"13","author":"K Banek","year":"2014","unstructured":"Banek K, Lalani M, Staedke SG, Chandramohan D. Adherence to artemisinin-based combination therapy for the treatment of malaria: a systematic review of the evidence. Malar J. 2014;13:7.","journal-title":"Malar J."},{"key":"3520_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1365-3156.2006.01784.x","volume":"12","author":"EA Ashley","year":"2007","unstructured":"Ashley EA, Stepniewska K, Lindeg\u00e5rdh N, Annerberg A, Kham A, Brockman A, et al. How much fat is necessary to optimize lumefantrine oral bioavailability? Trop Med Int Heal. 2007;12:195\u2013200.","journal-title":"Trop Med Int Heal."},{"key":"3520_CR15","doi-asserted-by":"publisher","first-page":"e001856","DOI":"10.1136\/bmjgh-2019-001856","volume":"4","author":"JD Challenger","year":"2019","unstructured":"Challenger JD, Gon\u00e7alves BP, Bradley J, Bruxvoort K, Tiono AB, Drakeley C, et al. How delayed and non-adherent treatment contribute to onward transmission of malaria: a modelling study. BMJ Glob Health. 2019;4:e001856.","journal-title":"BMJ Glob Health."},{"key":"3520_CR16","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12936-015-0813-1","volume":"14","author":"MT Bretscher","year":"2015","unstructured":"Bretscher MT, Maire N, Felger I, Owusu-Agyei S, Smith T. Asymptomatic Plasmodium falciparum infections may not be shortened by acquired immunity. Malar J. 2015;14:294.","journal-title":"Malar J."},{"key":"3520_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.epidem.2011.03.002","volume":"3","author":"MT Bretscher","year":"2011","unstructured":"Bretscher MT, Maire N, Chitnis N, Felger I, Owusu-Agyei S, Smith T. The distribution of Plasmodium falciparum infection durations. Epidemics. 2011;3:109\u201318.","journal-title":"Epidemics."},{"key":"3520_CR18","volume-title":"Methods for surveillance of antimalarial drug efficacy","author":"WHO","year":"2009","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009."},{"key":"3520_CR19","doi-asserted-by":"publisher","first-page":"e1001119","DOI":"10.1371\/journal.pmed.1001119","volume":"8","author":"D Atwine","year":"2011","unstructured":"Atwine D, Balikagala B, Bassat Q, Chalwe V, D\u2019Alessandro U, Dhorda M, et al. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 2011;8:e1001119.","journal-title":"PLoS Med."},{"key":"3520_CR20","doi-asserted-by":"publisher","first-page":"e2011026","DOI":"10.4084\/mjhid.2012.026","volume":"4","author":"A Bartoloni","year":"2012","unstructured":"Bartoloni A, Zammarchi L. Clinical aspects of uncomplicated and severe malaria. Mediterr J Hematol Infect Dis. 2012;4:e2011026.","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"3520_CR21","volume-title":"World malaria report 2018","author":"WHO","year":"2018","unstructured":"WHO. World malaria report 2018. Geneva: World Health Organization; 2018."},{"key":"3520_CR22","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S0140-6736(19)31097-9","volume":"394","author":"DJ Weiss","year":"2019","unstructured":"Weiss DJ, Lucas TCD, Nguyen M, Nandi AK, Bisanzio D, Battle KE, et al. Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum, 2000\u201317: a spatial and temporal modelling study. Lancet. 2019;394:322\u201331.","journal-title":"Lancet"},{"key":"3520_CR23","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12936-018-2500-5","volume":"17","author":"D Pfeffer","year":"2018","unstructured":"Pfeffer D, Lucas T, May D, Harris J, Rozier J, Twohig K, et al. MalariaAtlas: an R interface to global malariometric data hosted by the Malaria Atlas Project. Malar J. 2018;17:352.","journal-title":"Malar J."},{"key":"3520_CR24","unstructured":"www.latlong.net [Internet]. Available from: www.latlong.net."},{"key":"3520_CR25","unstructured":"Team SD. RStan\u202f: the R interface to Stan. 2020. p. R package version 2.21.1."},{"key":"3520_CR26","doi-asserted-by":"crossref","unstructured":"McElreath R. rethinking: Statistical rethinking book package. 2020. p. R package version 2.01.","DOI":"10.1201\/9780429029608"},{"key":"3520_CR27","unstructured":"McElreath R. Statistical rethinking: A bayesian course with examples in R and stan. 1st ed. Statistical Rethinking: A Bayesian Course with Examples in R and Stan. Chapman and Hall\/CRC; 2016."},{"key":"3520_CR28","doi-asserted-by":"publisher","first-page":"e45542","DOI":"10.1371\/journal.pone.0045542","volume":"7","author":"I Felger","year":"2012","unstructured":"Felger I, Maire M, Bretscher MT, Falk N, Tiaden A, Sama W, et al. The dynamics of natural Plasmodium falciparum infections. PLoS ONE. 2012;7:e45542.","journal-title":"PLoS ONE"},{"key":"3520_CR29","doi-asserted-by":"publisher","first-page":"12025","DOI":"10.1073\/pnas.0905922106","volume":"106","author":"ER Lozovsky","year":"2009","unstructured":"Lozovsky ER, Chookajorn T, Brown KM, Imwong M, Shaw PJ, Kamchonwongpaisan S, et al. Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proc Natl Acad Sci USA. 2009;106:12025\u201330.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3520_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/1475-2875-8-253","volume":"8","author":"NJ White","year":"2009","unstructured":"White NJ, Pongtavornpinyo W, Maude RJ. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J. 2009;8:253.","journal-title":"Malar J."},{"key":"3520_CR31","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1038\/ncomms6606","volume":"5","author":"LC Okell","year":"2014","unstructured":"Okell LC, Cairns M, Griffin JT, Ferguson NM, Tarning J, Jagoe G, et al. Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis. Nat Commun. 2014;5:5606.","journal-title":"Nat Commun."},{"key":"3520_CR32","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41467-017-01352-3","volume":"8","author":"JD Challenger","year":"2017","unstructured":"Challenger JD, Bruxvoort K, Ghani AC, Okell LC. Assessing the impact of imperfect adherence to artemether-lumefantrine on malaria treatment outcomes using within-host modelling. Nat Commun. 2017;8:1373.","journal-title":"Nat Commun."},{"key":"3520_CR33","doi-asserted-by":"publisher","first-page":"529","DOI":"10.4269\/ajtmh.2010.09-0334","volume":"82","author":"S Schoepflin","year":"2010","unstructured":"Schoepflin S, Lin E, Kiniboro B, DaRe JT, Mehlotra RK, Zimmerman PA, et al. Treatment with coartem (artemether-lumefantrine) in Papua New Guinea. Am J Trop Med Hyg. 2010;82:529\u201334.","journal-title":"Am J Trop Med Hyg"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03520-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12936-020-03520-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03520-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T07:57:57Z","timestamp":1607500677000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-020-03520-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3520"],"URL":"https:\/\/doi.org\/10.1186\/s12936-020-03520-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.08.21.20179382","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"26 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent for participation"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LCO declares prior grant funding from the World Health Organization in addition to the funding already declared in the acknowledgements. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"453"}}